Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00028301
Status:
COMPLETED
Last Update Posted:
2010-09-13
First Post:
2001-12-20
Brief Title:
Atazanavir Versus LopinavirRitonavir LPVRTV in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimens
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus LopinavirRitonavirLPVRTV Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimens
Status:
COMPLETED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood
Detailed Description:
The study is designed to determine the metabolic changes antiviral activity safety and tolerability of atazanavir as compared to LPVRTV each in combination with 2 nucleosides over the initial 24 weeks with a final analysis at 48 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI424-043 | None | None | None |